Modulation of antineoplastic activity of cyclophosphamide by Alstonia scholaris in the Ehrlich ascites carcinoma-bearing mice

Ganesh Chandra Jagetia, Manjeshwar Shrinath Baliga

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Alterations in the neoplastic activity of cyclophosphamide (CPA) by the extract of Alstonia scholaris (ASE) were studied in mice transplanted with Ehrlich ascites carcinoma (EAC). The tumor-bearing animals were injected with various doses of ASE and 25mg/kg of CPA (1/10th of the LD50 dose). The combination of 120mg/kg of ASE with 25mg/kg of CPA was most effective, as it caused the highest tumor regression and enhanced the mean survival time (MST) and the average survival time (AST) up to 42 and 40.7, as against the 29 and 27.5 of CPA alone, respectively. Similarly, when 120mg/kg of ASE was combined with different doses of CPA (3.125 to 50mg/kg), a dose-dependent increase in the anticancer activity was observed up to 25 mg/kg of CPA. However, a further increase in the CPA dose up to 37.5 or 50 mg/kg resulted in toxic side effects and death. The best effect was observed when 120 mg/kg of ASE was combined with 25 mg/kg followed by 12.5 mg/kg of CPA, as evident by the greater tumor remission, when compared with the concurrent doses of either drug alone. The administration of 120 mg/kg of ASE 6 h before the administration of 25 mg/kg of CPA resulted in a drastic decline in the glutathione levels and increased the lipid peroxidation considerably when compared with either drug alone.

Original languageEnglish
Pages (from-to)272-282
Number of pages11
JournalJournal of Experimental Therapeutics and Oncology
Volume3
Issue number5
DOIs
Publication statusPublished - 01-09-2003
Externally publishedYes

Fingerprint

Alstonia
Ascites
Antineoplastic Agents
Cyclophosphamide
Carcinoma
Neoplasms
Poisons
Lethal Dose 50
Pharmaceutical Preparations
Lipid Peroxidation
Glutathione

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

@article{6669ae01bc214a70b43278ab00f57237,
title = "Modulation of antineoplastic activity of cyclophosphamide by Alstonia scholaris in the Ehrlich ascites carcinoma-bearing mice",
abstract = "Alterations in the neoplastic activity of cyclophosphamide (CPA) by the extract of Alstonia scholaris (ASE) were studied in mice transplanted with Ehrlich ascites carcinoma (EAC). The tumor-bearing animals were injected with various doses of ASE and 25mg/kg of CPA (1/10th of the LD50 dose). The combination of 120mg/kg of ASE with 25mg/kg of CPA was most effective, as it caused the highest tumor regression and enhanced the mean survival time (MST) and the average survival time (AST) up to 42 and 40.7, as against the 29 and 27.5 of CPA alone, respectively. Similarly, when 120mg/kg of ASE was combined with different doses of CPA (3.125 to 50mg/kg), a dose-dependent increase in the anticancer activity was observed up to 25 mg/kg of CPA. However, a further increase in the CPA dose up to 37.5 or 50 mg/kg resulted in toxic side effects and death. The best effect was observed when 120 mg/kg of ASE was combined with 25 mg/kg followed by 12.5 mg/kg of CPA, as evident by the greater tumor remission, when compared with the concurrent doses of either drug alone. The administration of 120 mg/kg of ASE 6 h before the administration of 25 mg/kg of CPA resulted in a drastic decline in the glutathione levels and increased the lipid peroxidation considerably when compared with either drug alone.",
author = "Jagetia, {Ganesh Chandra} and Baliga, {Manjeshwar Shrinath}",
year = "2003",
month = "9",
day = "1",
doi = "10.1111/j.1533-869X.2003.01098.x",
language = "English",
volume = "3",
pages = "272--282",
journal = "Journal of Experimental Therapeutics and Oncology",
issn = "1359-4117",
publisher = "Old City Publishing",
number = "5",

}

Modulation of antineoplastic activity of cyclophosphamide by Alstonia scholaris in the Ehrlich ascites carcinoma-bearing mice. / Jagetia, Ganesh Chandra; Baliga, Manjeshwar Shrinath.

In: Journal of Experimental Therapeutics and Oncology, Vol. 3, No. 5, 01.09.2003, p. 272-282.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Modulation of antineoplastic activity of cyclophosphamide by Alstonia scholaris in the Ehrlich ascites carcinoma-bearing mice

AU - Jagetia, Ganesh Chandra

AU - Baliga, Manjeshwar Shrinath

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Alterations in the neoplastic activity of cyclophosphamide (CPA) by the extract of Alstonia scholaris (ASE) were studied in mice transplanted with Ehrlich ascites carcinoma (EAC). The tumor-bearing animals were injected with various doses of ASE and 25mg/kg of CPA (1/10th of the LD50 dose). The combination of 120mg/kg of ASE with 25mg/kg of CPA was most effective, as it caused the highest tumor regression and enhanced the mean survival time (MST) and the average survival time (AST) up to 42 and 40.7, as against the 29 and 27.5 of CPA alone, respectively. Similarly, when 120mg/kg of ASE was combined with different doses of CPA (3.125 to 50mg/kg), a dose-dependent increase in the anticancer activity was observed up to 25 mg/kg of CPA. However, a further increase in the CPA dose up to 37.5 or 50 mg/kg resulted in toxic side effects and death. The best effect was observed when 120 mg/kg of ASE was combined with 25 mg/kg followed by 12.5 mg/kg of CPA, as evident by the greater tumor remission, when compared with the concurrent doses of either drug alone. The administration of 120 mg/kg of ASE 6 h before the administration of 25 mg/kg of CPA resulted in a drastic decline in the glutathione levels and increased the lipid peroxidation considerably when compared with either drug alone.

AB - Alterations in the neoplastic activity of cyclophosphamide (CPA) by the extract of Alstonia scholaris (ASE) were studied in mice transplanted with Ehrlich ascites carcinoma (EAC). The tumor-bearing animals were injected with various doses of ASE and 25mg/kg of CPA (1/10th of the LD50 dose). The combination of 120mg/kg of ASE with 25mg/kg of CPA was most effective, as it caused the highest tumor regression and enhanced the mean survival time (MST) and the average survival time (AST) up to 42 and 40.7, as against the 29 and 27.5 of CPA alone, respectively. Similarly, when 120mg/kg of ASE was combined with different doses of CPA (3.125 to 50mg/kg), a dose-dependent increase in the anticancer activity was observed up to 25 mg/kg of CPA. However, a further increase in the CPA dose up to 37.5 or 50 mg/kg resulted in toxic side effects and death. The best effect was observed when 120 mg/kg of ASE was combined with 25 mg/kg followed by 12.5 mg/kg of CPA, as evident by the greater tumor remission, when compared with the concurrent doses of either drug alone. The administration of 120 mg/kg of ASE 6 h before the administration of 25 mg/kg of CPA resulted in a drastic decline in the glutathione levels and increased the lipid peroxidation considerably when compared with either drug alone.

UR - http://www.scopus.com/inward/record.url?scp=0347624650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347624650&partnerID=8YFLogxK

U2 - 10.1111/j.1533-869X.2003.01098.x

DO - 10.1111/j.1533-869X.2003.01098.x

M3 - Article

VL - 3

SP - 272

EP - 282

JO - Journal of Experimental Therapeutics and Oncology

JF - Journal of Experimental Therapeutics and Oncology

SN - 1359-4117

IS - 5

ER -